A clinical-stage biotech pioneer leveraging CAR-NK cell technology to treat autoimmune disorders and oncology with a robust balance sheet funded by recent capital raises.
Autolus offers significant upside potential as a first-in-class developer with differentiated CAR-NK technology that could redefine treatment for Type 1 Diabetes and other autoimmune conditions. The recent $550M capital infusion provides ample runway to advance multiple programs into pivotal late-stage trials without immediate pressure for profitability or asset sales.
Investors face substantial risk given the company's deep accumulated deficit of -$1.1B and recurring net losses exceeding $200M annually with no current revenue generation. The path to commercialization is long and uncertain, requiring successful outcomes in multiple clinical trials before any product launches or meaningful cash flow from sales materialize.
Autolus Therapeutics is a clinical-stage biotechnology company focused on developing first-in-class therapies for autoimmune diseases and oncology using its proprietary CAR-NK cell technology platform. The company primarily serves patients with conditions such as Type 1 Diabetes, Sjögren's syndrome, and various cancers through its pipeline of cellular immunotherapies. With significant cash reserves and recent equity issuances, the firm is positioned to advance multiple clinical programs toward late-stage trials and potential regulatory approval.
The company reported a net loss of $220.7M for the latest period, driven by substantial research and development expenditures of $138.4M and general administrative costs totaling $101.1M. Despite negative operating cash flow of $206.3M, the firm maintained a healthy liquidity position with ending cash of $228.8M following a $550M capital raise, allowing continued investment in its high-risk, high-reward clinical pipeline.
The cellular immunotherapy market is experiencing rapid growth driven by advancements in gene editing and cell engineering technologies for treating cancer and autoimmune diseases. Biotechnology firms are increasingly focusing on off-the-shelf NK cell therapies to overcome the manufacturing and toxicity challenges associated with autologous CAR-T products.
| Metric | 2023 | 2024 |
|---|---|---|
| Revenue | $0 | $10.1M |
| Cost of Revenue | $0 | $11.4M |
| Gross Profit | $0 | $-1.3M |
| Operating Expenses | $179.7M | $240.2M |
| Operating Income | $-179.7M | $-241.4M |
| R&D | $130.5M | $138.4M |
| G&A | $46.7M | $101.1M |
| Stock-Based Comp | $11.2M | $15.5M |
| D&A | $6.6M | $7.6M |
| Depreciation | $6.6M | $7.6M |
| Amortization | $0 | $162.0K |
| Other OpEx | $2.5M | $637.0K |
| Non-Operating Income | $-28.7M | $22.3M |
| Interest Expense | $45.1M | $9.3M |
| Interest Income | $13.5M | $32.4M |
| Pre-Tax Income | $-208.4M | $-219.1M |
| Income Tax | $-19.5K | $1.5M |
| Continuing Ops | $-208.4M | $-220.7M |
| Discontinued Ops | $-500 | $0 |
| Net Income | $-208.4M | $-220.7M |
| Minority Interest | $0 | $0 |
| Net to Common | $-208.4M | $-220.7M |
| Metric | 2023 | 2024 |
|---|---|---|
| Current Assets | $275.3M | $660.9M |
| Cash & Equivalents | $239.6M | $227.4M |
| Accounts Receivable | $109.0K | $15.0K |
| Inventory | — | $4.1M |
| Prepaid Expenses | $35.0M | $67.3M |
| Other Current Assets | $660.0K | $362.1M |
| Long-Term Assets | $100.1M | $121.8M |
| PP&E (Net) | $34.9M | $49.6M |
| Operating Leases | $60.8M | $55.5M |
| Other LT Assets | $4.4M | $16.7M |
| Total Assets | $375.4M | $782.7M |
| Current Liabilities | $44.7M | $60.7M |
| Accounts Payable | $103.0K | $2.0M |
| Current Leases | $5.1M | $3.0M |
| Deferred Revenue | — | $3.5M |
| Other Current Liab | $0 | $0 |
| Long-Term Liabilities | $219.2M | $294.7M |
| LT Operating Leases | $47.9M | $49.6M |
| Other LT Liab | $357.0K | $426.0K |
| Total Liabilities | $263.9M | $355.4M |
| Shareholders' Equity | $111.5M | $427.3M |
| Paid-In Capital | $1.02B | $1.56B |
| Retained Earnings | $-878.6M | $-1.10B |
| AOCI | $-29.0M | $-29.2M |
| Total L&E | $375.4M | $782.7M |
| Metric | 2023 | 2024 |
|---|---|---|
| Net Income (CFO) | $-208.4M | $-220.7M |
| Non-Cash Adjustments | $78.5M | $9.7M |
| Working Capital Changes | $-15.7M | $4.7M |
| Cash from Operations | $-145.6M | $-206.3M |
| Capital Expenditures | $11.0M | $22.1M |
| Cash from Investing | $-11.0M | $-394.6M |
| Cash from Financing | $-883.0K | $589.6M |
| FX Effect | $15.0M | $-261.0K |
| Net Change in Cash | $-142.4M | $-11.5M |
| Beginning Cash | $382.8M | $240.3M |
| Ending Cash | $240.3M | $228.8M |
Therapeutic Development Programs targeting Type 1 Diabetes, Sjögren's syndrome, and Oncology; Platform Technologies for CAR-NK cell manufacturing and delivery; Strategic Partnerships and Licensing Agreements.
High probability of clinical trial failure or delays common in early-stage biotechnology; Dependence on successful completion of costly Phase 2/3 trials to achieve commercial viability; Potential dilution from future equity issuances needed to fund operations and acquisitions.
Proprietary CAR-NK platform offering lower toxicity profiles compared to CAR-T therapies; Strong balance sheet with over $227M in cash providing runway for late-stage development; First-in-class status in multiple autoimmune indications addressing unmet medical needs.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.